Member Info for entoman

I am not saying any PREM director has done anything dishonest and they are unlikely to want to do so as being struck off as a director of PREM would also affect their directorships with other companies. A company would not be allowed to retain someone as a director if they have been ‘struck’ off elsewhere. Being struck off is not a trivial matter.

I am not sure GR will want PREM to become insolvent because independent insolvency practitioners will then scrutinize all aspects of the company including the directors for any wrong doing and if the latter are found to be at fault they can be struck off as directors or face legal proceedings against them.

So are we at stage 5: www.mines.gov.zw/?q=procedure-and-criteria-issuing-exclusive-prospecting-orders-epos

Monday's RNS stated 'I am pleased to confirm that a further invitation has been received by Zulu Lithium and Tantalum to attend at the Ministry of Mines in Harare later this week for interviews pursuant to the finalisation of our application for an Exclusive Prospecting Order. ' Hopefully this will result in the EPO being signed off soon and a JV partner announced...

As US$6 million has been stated in three RNS and reference made to a new legally binding agreement with NIEEF being signed that includes a funding undertaking of US$6 million for RHA I cannot see how they can accept RTGS Dollars instead of US$... For PREM to agree to a one to one RTGS to US$ conversion is absurd.

(1) Update on RHA
Wed, 13th Mar 2019 12:55
Premier African Minerals Limited ("Premier" or the "Company") is pleased to report that the Company received a letter on the afternoon of 12 March from the Zimbabwe Ministry of Industry, Commerce and Enterprise Development ("Ministry") which states that the Ministry has secured a proposed investment of US$6 million investment into RHA Tungsten (Private) Limited ("RHA") for the immediate recommissioning of mining operations, subject to completion of the appropriate agreements.
(2) Update on the Acquisition of Mining Assets
Wed, 17th Apr 2019 07:00
Premier notes that pursuant to our announcement on 13 March 2019, the final agreements are with the office of the Ministry of Industry, Commerce and Enterprise Development ("Ministry") and Premier now awaits final sign-off.
(3) RHA Investment and Management Agreement
Tue, 7th May 2019 07:00
George Roach, CEO of Premier commented: "Whilst it has been a long haul, I am very pleased to be able to report that we have signed a new legally binding agreement with NIEEF that includes a funding undertaking of US$6 million for RHA.
Perhaps though PREM did know a month ago they would receive RTGS $ as the Corporate Update of
Tue, 28th May 2019 16:18 referred to $6 million and not to US$6 million:
The Company's agreement with NIEEF in respect of RHA Tungsten, (as announced on 7 May 2019) has a binding provision for NIEEF to provide financing of $6 million.

Or more likely Zim Govt. told him he could not use them for KME ... so now they will arrive..

I thought we had interest in the Togo Dapaong Project Gold mine as well as Casa Mining gold mine. If not why are these still shown as projects on the website.

Hopefully this is not another example of “All that glitters is not gold”

Has anyone found any information about Honey Badger Resources Limited (HBR) as nothing seems to be on the net.... Interestingly HBR on the London Stock Exchange is the symbol for a company called 'Holidaybreak' that is no longer trading ! It is also not a Zimbabwe listed company..

I believe it could be used to interpret gallstone scan data - see my post of 11 December.

As far as I can see no additional equipment will need to be purchased by a NHS Trust or private hospital that is already carrying out CT scans and lithotripsy procedures. The stonechecker medical software will be loaded by the hospital IT department for use by the urology department and it will interrogate the data generated from the patient’s CT scan slices to determine the potential outcome of a lithotripsy procedure. Determining the selling price of the software is more difficult as it requires a health economic assessment to determine the cost of treating a patients kidney stones with or without using the stone checker product and from this the saving use of the software provides. With regard to the number of sales it would likely be one copy of the stonechecker product per NHS trust. There are some 135 acute non-specialist trusts and 17 acute specialist trusts (152 total) in England that could purchase the product. In a previous post I wrote that if the software reduced the number of treatments carried out by the NHS by just 5% it would equate to a saving of around £1.967 million per year. The difficult question though is what % of this would the company want and the NHS be prepared to give up to purchase the software. As you rightly suggest private hospitals may also be interested in the software as many of them will provide a urology service / kidney stone removal though it is difficult to determine how many private hospitals do provide this service without spending hours searching the web. The cost of kidney stone treatment in private hospitals is likely to be £1,000 to £3,000.

At Derby Teaching Hospitals NHS Foundation Trust a course of treatment to remove kidney stones is 3 sessions https://www.derbyhospitals.nhs.uk/easysiteweb/getresource.axd?assetid=2912&type=0&servicetype=1 . In an earlier post I indicated that in 2013-14 the number of hospital admissions for kidney – or renal – stone treatment was 93,039 and the cost to the NHS of an extracorporeal lithotripsy session is £423 as a day case. If the StoneChecker Software reduced the number of treatments carried out by the NHS by just 5% (4,651 treatments) this equates to a minimum saving of £1.967 million per year for the NHS. The larger market is of course in the US where kidney stones affect about 1 out of 11 Americans (9% of the 325 million population). The prevalence of kidney stones among Americans has nearly doubled in the last 15 years, and is increasing in both adults and children. According to the National Institute of Diabetes and Digestive and Kidney Diseases, kidney stones cost an estimated $10 billion each year, making them the most expensive non-malignant urologic condition in the United States https://dcri.org/kidney-stone-trial/. In the US kidney stone treatment can cost from just under $10,000 to $20,000 or more for surgical removal or extracorporeal shock wave lithotripsy (ESWL) http://health.costhelper.com/kidney-stone.html . Gaining US FDA approval in Q2 2018 will open up the US market and has the potential to provide significant revenue generation. .

Hi Leapfrog, I have only recently invested in FBDU and have had no communication with the company. My knowledge of the equipment is what I gleaned from the company website, RNS and general sources on the net plus knowledge gained from working with the NHS and healthcare technologies. The StoneChecker Software determines from a patient’s CT scan slices the potential outcome of a lithotripsy procedure carried out on their kidney stone. Being able to fracture the stone with fewer shock wave procedures and more accurately / quickly obtain smaller sized pieces of stone that can be passed out of the kidney will make for a cheaper therapy and better outcome for the patient. The cost to the NHS of an extracorporeal lithotripsy session is £423 as a day case so reducing the number of clinical sessions a patient needs to break up their kidney stones is potentially a cost saving of £423 per day for the NHS. This is a simplistic way to look at this but it does demonstrate one benefit to the NHS of the StoneChecker Software.

StoneChecker has an exclusive worldwide licence to apply the TexRAD® algorithm for exclusive use in urolithiasis (the formation of stony concretions in the bladder or urinary tract) to examine heterogeneity and ‘texture’ of stones not visible to the naked eye. In addition to using the software to examine kidney stones the technology could possibly also (subject to agreeing licence terms with TexRAD) be applied to the examination of gallstones prior to treatment. About 66,660 cholecystectomies (removal of the gallbladder) are performed every year in the NHS and around 61,220 of these are laparoscopic cholecystectomies. In cases where the gallstones are in the bile duct the stones can be treated by extracorporeal shock wave lithotripsy as is performed with kidney stones.

There are a number of ways the software could be sold to NHS Trusts. It could for instance be sold for a one-off fee; an annual fee or pay per click (per patient fee) or a mixture of these. It has been reported that the number of hospital admissions for kidney – or renal – stone treatment in England had increased by 20% in seven years, from 77,868 in 2006-07 to 93,039 in 2013-14. The incidence of stone disease in England has historically been reported at 10%, but the current data suggests that figure now stands at 14% – which means one in seven people will require hospital admission or treatment.

As a CEO of a NHS related company I deal on a daily basis with new innovations generated by the NHS and its university partners. Uptake by the NHS of the StoneChecker kidney stone product post CE mark will require evidence that the device is of clinical benefit for patients attending urology clinics in the 152 acute specialist and non-specialist English NHS trusts (employing 1,248 urology consultants and registrars) plus private hospitals and that it provides a cost saving for the NHS. From the evidence provided on the company website it appears to do both of these and this is why I purchased shares in the company. Hopefully the board is in discussions with the 15 Academic Health Science Networks across England that are tasked with improving health and generating economic growth in their regions which includes creating the right environment, and supporting collaboration across boundaries, in order to adopt and spread innovation at pace and scale www.ahsnnetwork.com/innovation/nhs-innovation-accelerator-nia

Nice RNS setting out the companies current position, the market for NGG biomarker assays and what the company aims to do noving forward. I wish more of the companies I am invested in would give such informative news releases!

I have access to UK and Irish company information via FAME (https://fame2.bvdep.com/version-2010628/Home.serv?product=fameneo) via my work.

Company information I have access to shows that on 7th July 2009 NGG owned 24% of Exetek.